SBIR/STTR Research Award

Software Relating Genes to Disease and Clinical Outcomes

Award identifier 93ab7c80f29c5fa41f2dab22d9f90bf9bee21e988542707a5f921140c56c8360Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,650

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Golden Helix, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
NUQLGUDRCBW8
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Applicant's abstract): The development of a software system is proposed that will combine statistical theory, computer science algorithms, and genetics expertise to take advantage of the great influx of data generated by both the study of the human genome and the creation of inexpensive genotyping techniques. This software will elucidate the complex relationship between drug efficacy and side effects, and multiple interacting genes and environmental factors. Preliminary results, obtained by using simulated data, indicate that it might be feasible to link phenotype to genotype for a list of "candidate genes." The statistical methods are expected to be successful even if the disease mechanism can differ from one person to another. By analyzing and interpreting clinical trial data, the software will match drugs to target populations according to their specific genotype. This will enable pharmaceutical companies to create novel drugs that render maximum effectiveness and have minimum side effects, i.e. the right drug for the right person. PROPOSED COMMERCIAL APPLICATION: The target markets for the research include pharmaceutical companies, CRO'S universities, and government agencies. It has good potential for commercialization because it is expected to help create novel drugs, boost the safety of drug treatments, save substantial resources, and make sense of complex genotype/phenotype relationships in clinical trials context.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

9 SBIR/STTR records share this UEI (2001–2025). Reported award amounts total $6,090,395. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.